Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05905926 Enrolling by invitation - Clinical trials for Irritable Bowel Syndrome With Constipation (IBS-C)

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Start date: February 17, 2023
Phase: Phase 3
Study type: Interventional

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

NCT ID: NCT05905328 Recruiting - Clinical trials for Cytokine Release Syndrome

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Start date: December 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15 days.

NCT ID: NCT05905107 Recruiting - Clinical trials for Carpal Tunnel Syndrome

Neurodynamic Sequencing in Patients With Carpal Tunnel Syndrome

Start date: January 4, 2023
Phase: N/A
Study type: Interventional

Carpal tunnel syndrome is a compressive neuropathy of median nerve in the fascial tunnel at wrist which causes pain, numbness ,and tingling in the extremities. Common treatment options used in the treatment of carpal tunnel syndrome are conservative and surgical treatment option is better, this question is still a topic requiring more and more clinical trials. Neuromobilisation described by Butler is one of the treatment options which are used in the treatment of carpal tunnel syndrome in conjunction with other conservative measures. This proposed study will find out the effectiveness of Neuromobilisation in treatment of carpal tunnel syndrome. As there is very little evidence available which Neuromobilisation technique is effective and what are the types of patients which can get benefit from this technique. This study will find out the effect of Neuromobilisation in patients suffering from carpal tunnel syndrome of non traumatic origin. This is a randomized clinical trial. Target population is patients suffering from carpal tunnel syndrome of non-traumatic origin. Data will be collected from District Headquarter Hospital Faisalabad. This study will include 56 participants according to the selection criteria. The participants will be randomly divided into two groups through sealed opaque envelop method. Group A will recruit 28 patients which fulfill the inclusion criteria. These patients will be treated by nerve sequencing proximal to distal in 3 sets of 15 repetitions in one session on alternate days for 4 weeks. Group B will recruit 28 patients which fulfill the inclusion criteria. These patients will be treated by nerve sequencing distal to proximal in 3 sets of 10 repetitions in one session for 4 weeks. The Statistical analysis will be performed through SPSS Software 21.

NCT ID: NCT05904821 Completed - Down Syndrome Clinical Trials

Relationship Between BMI, Physical Fitness and Motor Skills in Children With Down's Syndrome

Start date: May 23, 2023
Phase:
Study type: Observational

Down syndrome is a congenital condition which includes physical mental, and functional abnormalities. It arises from defect involving chromosome 21, usually an extra copy (trisomy 21). Purpose of this study will determine the relationship between BMI, physical fitness and motor skills in youth with down syndrome

NCT ID: NCT05904561 Completed - Clinical trials for Carpal Tunnel Syndrome

Effect of Low Level Laser Therapy Versus Pulsed Ultrasound

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Carpal tunnel syndrome (CTs), the most common entrapment neuropathy of the upper extremity, is caused by compression of the median nerve as it travels through the carpal tunnel. CTs was clinically diagnosed in more than half of women (62%). Neurophysiological evaluation diagnosed that CTs in around half of women (43%) was positive in one hand at least, also, it was reported that about half of women with CTs during pregnancy still complained of CTs symptoms one year after delivery.

NCT ID: NCT05904301 Recruiting - Clinical trials for Rheumatoid Arthritis

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

NAREG
Start date: June 21, 2023
Phase:
Study type: Observational

Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.

NCT ID: NCT05904197 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Effectiveness of Educational Gamified Cards About Nephrotic Syndrome

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the effectiveness of educational innovative gamified cards about nephrotic syndrome for school age children on their outcomes and caregivers' practices

NCT ID: NCT05903976 Recruiting - Clinical trials for Coronary Artery Disease

De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS

DESC-HBR
Start date: June 12, 2023
Phase: Phase 3
Study type: Interventional

High bleeding risk (HBR) patients, comprising up to 50% of those presenting with acute coronary syndrome (ACS), are a high-risk group that is increasing in size due to an aging population. The optimal selection of the potency and duration of antiplatelet therapy to reduce the risk of recurrent ischemic and bleeding events in HBR patients is still a matter of debate. Multiple strategies to reduce bleeding during secondary prevention, such as reducing the duration of dual antiplatelet therapy, using single antiplatelet therapy with a P2Y12 inhibitor, or de-escalating to a lower potency or lower-dose P2Y12 inhibitor, have been proposed. De-escalation to a lower potency or lower-dose P2Y12 inhibitor is particularly attractive because it maintains efficient pharmacological inhibition of multiple platelet pathways while potentially reducing bleeding through less aggressive activity. Yet, there has been no study comparing the effects of different de-escalation strategies with the standard potent P2Y12 inhibitors in HBR patients. The aim of the DESC-HBR study is to assess the impact of de-escalating P2Y12 inhibitor to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg bid in HBR patients, in comparison with full-dose potent P2Y12 inhibitors, on the proportion of patients with optimal platelet reactivity (OPR). Secondary objectives involve exploring the effect of de-escalation on clinical events and patients' quality of life.

NCT ID: NCT05903404 Recruiting - Clinical trials for Polycystic Ovary Syndrome

PCOS Indirect and Intangible Economic Burden

PCOSCHALLENGE
Start date: June 22, 2022
Phase:
Study type: Observational [Patient Registry]

The primary purpose of the PCOS Indirect and Intangible Economic Buren study is to estimate the economic costs of having PCOS in terms of quality of life and work productivity. The population will include individuals with a clinical diagnosis of PCOS, individuals self-diagnosed with PCOS, individuals with symptoms of PCOS (e.g., hirsutism, irregular menstrual cycles), and demographic-matched controls without PCOS. This study is a sub-study of The PCOS Challenge Study.

NCT ID: NCT05903274 Recruiting - Clinical trials for Lower-risk Myelodysplastic Syndrome

JSP191 (Briquilimab) in Subjects With LR-MDS

Start date: June 19, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.